Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were ob...
Na minha lista:
| Publicado no: | Ann Rheum Dis |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
1978
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC1000198/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/343727/ https://ncbi.nlm.nih.govhttps://doi.org/10.1136/ard.37.1.85 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|